Journal article
AP-2α and AP-2γ are transcriptional targets of p53 in human breast carcinoma cells
Oncogene, Vol.25(39), pp.5405-5415
2006
DOI: 10.1038/sj.onc.1209534
PMID: 16636674
Abstract
Activating enhancer-binding protein 2alpha (AP-2alpha) and activating enhancer-binding protein 2gamma (AP-2gamma) are transcription factors that bind GC-rich consensus sequences and regulate the expression of many downstream genes. AP-2alpha and AP-2gamma interact with p53 both physically and functionally. Expression microarray results in human breast carcinoma cells with forced p53 expression revealed AP-2gamma as a putative transcriptional target of p53. To confirm and extend these findings we measured the effects of forced p53 expression in human breast carcinoma cells by real-time reverse transcription-PCR, Western blotting, electrophoretic gel mobility shift assays, promoter reporter, chromatin immunoprecipitation and chromatin accessibility assays. Wild-type p53 expression rapidly induced not only AP-2gamma but also AP-2alpha mRNA. The subsequent increase in these proteins led to increased AP-2 DNA-binding and transactivating activity. Candidate p53-binding sites were identified in the AP-2alpha and AP-2gamma promoters. p53 binding to these cis-elements in vivo was also observed, together with a relaxation of chromatin structure in these regions. Finally, expression of either AP-2alpha or gamma inhibited growth of human breast carcinoma cells in vitro. Taken together, our findings indicate that these AP-2 genes are targets for transcriptional activation by p53 and suggest that AP-2 proteins may mediate some of the downstream effects of p53 expression such as inhibition of proliferation.
Details
- Title: Subtitle
- AP-2α and AP-2γ are transcriptional targets of p53 in human breast carcinoma cells
- Creators
- H LI - Department of Radiation Oncology, Free Radical and Radiation Biology Program, University of Iowa, Iowa City, IA, United StatesG. S WATTS - Bone Marrow Transplant Program, Arizona Cancer Center and Department of Pharmacology and Toxicology, The University of Arizona, Tucson, AZ, United StatesM. M OSHIRO - Bone Marrow Transplant Program, Arizona Cancer Center and Department of Pharmacology and Toxicology, The University of Arizona, Tucson, AZ, United StatesB. W FUTSCHER - Bone Marrow Transplant Program, Arizona Cancer Center and Department of Pharmacology and Toxicology, The University of Arizona, Tucson, AZ, United StatesF. E DOMANN - Department of Radiation Oncology, Free Radical and Radiation Biology Program, University of Iowa, Iowa City, IA, United States
- Resource Type
- Journal article
- Publication Details
- Oncogene, Vol.25(39), pp.5405-5415
- DOI
- 10.1038/sj.onc.1209534
- PMID
- 16636674
- NLM abbreviation
- Oncogene
- ISSN
- 0950-9232
- eISSN
- 1476-5594
- Publisher
- Nature Publishing; Basingstoke
- Language
- English
- Date published
- 2006
- Academic Unit
- Pathology; Surgery; Radiation Oncology
- Record Identifier
- 9984047999102771
Metrics
26 Record Views